Durability of Proximal Femur Replacements: A Forty Year Experience

Rishi Trikha¹, Danielle Greig, Erik John Geiger², Thomas Olson, Lauren Elisabeth Wessel, Nicholas M Bernthal³ ¹UCLA Department of Orthopaedic Surgery, ²UCSF Department of Orthopaedics, ³UCLA, Dept. of Orthopaedic Surgery INTRODUCTION:

Proximal femoral replacements (PFRs) are an effective surgical option for the treatment of primary and metastatic tumors causing large bony defects. Increased interest in acetabular wear and the rarity of these indications has made the understanding of the durability of these implants and their mechanisms of failure crucial. METHODS:

All patients undergoing a primary or revision PFR for an oncologic diagnosis at a single institution between 1982-2020 were reviewed. This study utilized the validated Henderson Failure Classification and characterized the failures as soft tissue failures (type 1), aseptic loosening (type 2), structural failures (type 3), infection (type 4) or tumor progression (type 5). Statistical significance was defined as p < 0.05 using an unpaired t-test or chi square, where applicable. RESULTS:

132 PFRs performed on 124 patients were included, including 122 primary and 10 revision PFRs. Average age at time of first surgery was 47.32 years (range: 6.3–85.5) for patients undergoing primary PFR and 40.4 years (range: 17.3–60.1) for patients undergoing revision (Table 1). Chondrosarcoma and metastatic disease (each 27/122; 22.1%) were the most common diagnoses for primary reconstruction followed by osteosarcoma (21/122; 17.2%).

11 out of 122 primary PFRs (9.0%) failed at a mean time of 111.49 months, while 3 out of 10 revision PFRs (30.0%) failed at a mean time of 120.51 months (Table 2). There was an infection rate of 2.5% (3/122) for primary PFRs and 10% (1/10) for revision PFRs. Mean follow-up time for primary PFRs was 62.03 months and mean follow-up time for revision PFRs was 143.89 months. Segment/resection length was not significantly associated with primary or revision PFR failures (p=0.381 and 0. 274, respectively). Stem length was also not significantly associated with primary or revision PFR failures (p=0.797 and 0.826, respectively).

DISCUSSION AND CONCLUSION:

Neither stem length nor resection length was correlated with PFR failure. This is perhaps due to the stem location of PFRs being more distal and not being subjected to a higher magnitude of muscular deforming forces and subsequent intramedullary movement over time compared to the more proximal stems of distal femoral replacements. The rate of infection for PFRs was also relatively low in this dataset, possibly due to the meticulous soft tissue reconstruction using the muscles of the hip for implant coverage. The current study represents one of the largest available on PFRs over a 40hiahliahts remarkable durability studv period and the of these year implants.

	olday	ponoa	ana		9	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		10	mai	nubio		aarabiiity		
Implant Survival Curve Comparing Primary vs. Revision Proximal Femur Replacements				Table 1: Demographic and Implant Measurement Data						Table 2: Types of Proximal Femur Replacement Failures				
			ſ	Primary PFR		Total (N = 122)	Non-Failure (N = 111)	on-Failure (N = 111) Primary Failure (N = 11)	P-Value			Incidence of		Incidence of Subsequent
		Primary PFRs Revision PFRs		Age (years) Gender	Mean ± SD Range	6.29 - 85.48 45.90	48.32 ± 22.29 6.29 - 85.48 45.95	37.27 ± 19.26 8.11 - 73.24	0.116		Type of Failure	Failure	Time to Failure Mean ± SD (Months)	Failure N (%)
					Male (%) Female (%)			45.46	0.975			N (%)		
				Follow-Up (months)	Mean ± SD	54.10 62.03 ± 72.71	54.05 56.88 ± 71.74	54.55 111.49 ± 69.61	0.018	Primary	Aseptic loosening	3/122 (2.45)	53.55 ± 8.77	1/3 (33.33)
				Pollow-Op (months)	Median	31.76	24.48	86.24	0.018		Structural failure		149.87 ± 86.39	3/4 (75.00)
				Segment length (mm)	Mean ± SD	188.85 ± 109.39	183.71 ± 111.57	217.25 ± 88.95	0.381		Infection	3/122 (2.45)	32.66 ± 45.23	2/3 (66.67)
				segment tengen (mm)	Median	175	170	220.00	0.561		Tumor progressio	on 1/122 (0.82)	87.78	0/1 (0)
				Stem length (mm)	Mean ± SD	1/5 132.35 ± 30.54	132.26 ± 31.36	132.57 ± 24.16	0.797		Total	11/122 (9.02)	111.49 ± 88.18	6/11 (54.54)
				stem length (mm)	Median	132.35 ± 30.54	132.26 1 31.36	132.57 1 24.16	0.797	Revision	Soft-tissue failure	e 0/10 (0)	N/A	N/A
				Revision PFR	Median	127 Total (N = 10)	Non-Failure (N = 7)	Revision Failure (N = 3)	P-Value		Aseptic loosening		110.70	0/1 (0)
											Infection	1/10 (10)	10.59	0/1 (0)
				Age (years)	Mean ± SD Range	40.40 ± 16.44 17.33 - 60.12	38.46 ± 17.15 17.33 - 58.41	44.93 ± 17.04	0.600		Tumor progressio		N/A	N/A
				Gender	Male (%)	40.0	28.57	26.51 - 60.12	0.260		Total	3/10 (30)	120.51 ± 115.15	0/3 (0)
				Gender		60.0	71.43	66.67 0. 33.33	0.200					
				Follow-Up (months)	Mean ± SD	143.89 ± 81.23	155.57 ± 69.00	120.51 ± 115.15	0.577					
				Follow-Up (months)	Median	145.89±81.25 183.48	155.57 ± 69.00	120.51 £ 115.15	0.577					
				Segment length (mm)	Mean ± SD	195.67 ± 110	166.67 ± 115.53	256.67 ± 83.27	0.274					
				Jegment iengen (min)	Median	150	120	230	0.274					
				Stem length (mm)	Mean ± SD	123.89 ± 28.19	125.5 ± 29.63	120.67 ± 31.01	0.826					
					Median	127	127	120						
	5 10	15 20												
	Years													

Years Figure 1: Implant survival curve of primary PFRs to revision PFRs demonstrating that PFRs remain durable reconstruction option for this patient population.